STEP 1
New England Journal of Medicine
68 weeks
Once-Weekly Semaglutide in Adults with Overweight or Obesity
In STEP 1, adults without diabetes receiving 2.4 mg once-weekly subcutaneous semaglutide plus lifestyle intervention had a mean 14.9% body-weight reduction at 68 weeks, versus 2.4% with placebo.
- Studied regimen
- 2.4 mg once weekly plus lifestyle intervention
Published studies have evaluated specific semaglutide and tirzepatide regimens. Those results do not establish the effectiveness of Zenbody’s compounded formulations or predict an individual patient’s results.
View published research DOI 10.1056/NEJMoa2032183

